Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CAPRICOR THERAPEUTICS, INC.CAPR · Entity 5337 | Chief Medical Officer | July 24, 2018 | July 25, 2018 |
| Longeveron Inc.LGVN · Entity 7608 | Director | August 19, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CAPRICOR THERAPEUTICS, INC.
Report date July 24, 2018 · Filed July 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2018-07-24 | Direct | 50,000 |
Reported balance
After 2018-07-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-07-24 · Grant · Acquired 50,000 · Balance 50,000 F1: 1/48th of the shares subject to the stock option award shall vest on the first day of each month, commencing August 1, 2018, until the stock option becomes fully vested and exercisable. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the stock option award shall vest on the first day of each month, commencing August 1, 2018, until the stock option becomes fully vested and exercisable. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting.
Longeveron Inc.
Report date August 19, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 36,000 |
Reported balance
After 2026-08-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-19 · Grant · Acquired 36,000 · Balance 36,000 F1: Represents the award of time-based vesting Restricted Stock Units (RSUs). F2: Includes RSUs subject to future vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of time-based vesting Restricted Stock Units (RSUs).
F2: Includes RSUs subject to future vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2026 Filed Aug 21, 2026 22:00 UTC | Longeveron Inc. LGVN · Entity 7608 | GrantClass A Common Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-010737 · marketforms-73828.xml · nonDerivative · entry 1 Ascheim Deborah · CIK 0001649531 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 F1 · shares: Represents the award of time-based vesting Restricted Stock Units (RSUs). F2 · balance_after: Includes RSUs subject to future vesting. Read SEC document |
| July 24, 2018 Filed Jul 25, 2018 21:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001144204-18-039922 · tv499203_4.xml · derivative · entry 1 Ascheim Deborah · CIK 0001649531 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2018-07-24 F1 · derivative.exercise_date: 1/48th of the shares subject to the stock option award shall vest on the first day of each month, commencing August 1, 2018, until the stock option becomes fully vested and exercisable. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:01 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (right to buy) · Derivative | 43,122 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001144204-18-000854 · tv482713_4.xml · derivative · entry 1 Ascheim Deborah · CIK 0001649531 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,122 Underlying: Common Stock · 43,122 shares Expires 2028-01-02 F1 · derivative.exercise_date: 35,000 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2018, until the stock option becomes fully vested and exercisable. The remaining 8,122 shares will vest 1/12 on the first day of each month, commencing February 1, 2018, with the last month vesting on December 31, 2018. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 02:40 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001144204-17-000699 · v456174_4.xml · derivative · entry 1 Ascheim Deborah · CIK 0001649531 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-01-03 F1 · derivative.exercise_date: 1/48th of the shares subject to the stock option award shall vest on the first day of each month, commencing February 1, 2017, until the stock option becomes fully vested and exercisable. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. F1 · derivative.expiration_date: 1/48th of the shares subject to the stock option award shall vest on the first day of each month, commencing February 1, 2017, until the stock option becomes fully vested and exercisable. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.